PhytoHealth Corporation (4108.TW)
TWD 13.15
(0.0%)
TWD 13.15
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -34.64 Million TWD | 50.7% |
| 2022 | -70.26 Million TWD | -11.41% |
| 2021 | -63.07 Million TWD | -43.73% |
| 2020 | -43.88 Million TWD | 53.55% |
| 2019 | -94.48 Million TWD | 30.25% |
| 2018 | -135.46 Million TWD | -84.99% |
| 2017 | -73.22 Million TWD | 73.01% |
| 2016 | -271.35 Million TWD | 66.36% |
| 2015 | -806.66 Million TWD | -1633.09% |
| 2014 | -46.54 Million TWD | 50.6% |
| 2013 | -94.21 Million TWD | 93.95% |
| 2012 | -1.55 Billion TWD | -330.3% |
| 2011 | -361.97 Million TWD | -9.49% |
| 2010 | -330.58 Million TWD | -37.71% |
| 2009 | -240.05 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -34.25 Million TWD | 1.11% |
| 2024 Q2 | -21.73 Million TWD | 36.56% |
| 2023 Q3 | -16.41 Million TWD | 47.89% |
| 2023 Q4 | -34.64 Million TWD | -111.08% |
| 2023 FY | -34.64 Million TWD | 50.7% |
| 2023 Q1 | -59.5 Million TWD | 15.32% |
| 2023 Q2 | -31.49 Million TWD | 47.07% |
| 2022 Q3 | -89.04 Million TWD | 9.76% |
| 2022 Q2 | -98.68 Million TWD | -3.5% |
| 2022 FY | -70.26 Million TWD | -11.41% |
| 2022 Q1 | -95.34 Million TWD | -51.17% |
| 2022 Q4 | -70.26 Million TWD | 21.09% |
| 2021 Q1 | -60.88 Million TWD | -38.75% |
| 2021 Q2 | -48.2 Million TWD | 20.83% |
| 2021 FY | -63.07 Million TWD | -43.73% |
| 2021 Q3 | -46.48 Million TWD | 3.57% |
| 2021 Q4 | -63.07 Million TWD | -35.69% |
| 2020 FY | -43.88 Million TWD | 53.55% |
| 2020 Q3 | -73.25 Million TWD | 48.02% |
| 2020 Q1 | -66.56 Million TWD | 29.55% |
| 2020 Q2 | -140.92 Million TWD | -111.72% |
| 2020 Q4 | -43.88 Million TWD | 40.09% |
| 2019 Q1 | -84.23 Million TWD | 37.81% |
| 2019 Q3 | -81.09 Million TWD | 7.68% |
| 2019 Q4 | -94.48 Million TWD | -16.51% |
| 2019 FY | -94.48 Million TWD | 30.25% |
| 2019 Q2 | -87.83 Million TWD | -4.28% |
| 2018 Q2 | -72.09 Million TWD | 26.47% |
| 2018 Q3 | -76.09 Million TWD | -5.54% |
| 2018 Q4 | -135.46 Million TWD | -78.02% |
| 2018 Q1 | -98.05 Million TWD | -33.9% |
| 2018 FY | -135.46 Million TWD | -84.99% |
| 2017 Q1 | -22.99 Million TWD | 91.53% |
| 2017 FY | -73.22 Million TWD | 73.01% |
| 2017 Q4 | -73.22 Million TWD | -144.04% |
| 2017 Q3 | -30 Million TWD | -869.19% |
| 2017 Q2 | -3.09 Million TWD | 86.53% |
| 2016 Q2 | -591.52 Million TWD | -3.51% |
| 2016 Q1 | -571.47 Million TWD | 29.16% |
| 2016 FY | -271.35 Million TWD | 66.36% |
| 2016 Q3 | -373.61 Million TWD | 36.84% |
| 2016 Q4 | -271.35 Million TWD | 27.37% |
| 2015 Q2 | -1.09 Billion TWD | -232.06% |
| 2015 FY | -806.66 Million TWD | -1633.09% |
| 2015 Q4 | -806.66 Million TWD | 15.04% |
| 2015 Q3 | -949.44 Million TWD | 13.29% |
| 2015 Q1 | -329.74 Million TWD | -608.44% |
| 2014 Q2 | -114.28 Million TWD | 4.9% |
| 2014 Q1 | -120.17 Million TWD | -27.55% |
| 2014 Q3 | -61.12 Million TWD | 46.52% |
| 2014 Q4 | -46.54 Million TWD | 23.85% |
| 2014 FY | -46.54 Million TWD | 50.6% |
| 2013 Q1 | -110.48 Million TWD | 92.91% |
| 2013 Q3 | -101.62 Million TWD | -3.34% |
| 2013 Q2 | -98.34 Million TWD | 10.99% |
| 2013 FY | -94.21 Million TWD | 93.95% |
| 2013 Q4 | -94.21 Million TWD | 7.3% |
| 2012 Q2 | -348.4 Million TWD | 2.33% |
| 2012 FY | -1.55 Billion TWD | -330.3% |
| 2012 Q1 | -356.72 Million TWD | 1.45% |
| 2012 Q4 | -1.55 Billion TWD | -330.8% |
| 2012 Q3 | -361.55 Million TWD | -3.77% |
| 2011 Q2 | -331.97 Million TWD | -4.28% |
| 2011 Q1 | -318.35 Million TWD | 3.7% |
| 2011 Q3 | -363.39 Million TWD | -9.47% |
| 2011 Q4 | -361.97 Million TWD | 0.39% |
| 2011 FY | -361.97 Million TWD | -9.49% |
| 2010 FY | -330.58 Million TWD | -37.71% |
| 2010 Q4 | -330.58 Million TWD | 0.0% |
| 2009 FY | -240.05 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Grape King Bio Ltd | -4.62 Billion TWD | 99.251% |
| Standard Chem & Pharm CO., LTD. | -954.74 Million TWD | 96.372% |
| Maywufa Company Ltd. | 264.18 Million TWD | 113.112% |
| ScinoPharm Taiwan, Ltd. | -3.32 Billion TWD | 98.957% |
| Lotus Pharmaceutical Co., Ltd. | 9.81 Billion TWD | 100.353% |
| LIWANLI Innovation Co., Ltd. | -244.02 Million TWD | 85.804% |
| YungShin Global Holding Corporation | -247.5 Million TWD | 86.004% |
| SCI Pharmtech, Inc. | 100.41 Million TWD | 134.497% |
| Formosa Laboratories, Inc. | 2.53 Billion TWD | 101.365% |
| PharmaEssentia Corporation | -18.46 Billion TWD | 99.812% |
| Bora Pharmaceuticals Co., LTD. | 1.95 Billion TWD | 101.771% |